PM360

MAY 25, 2023

ChatGPT is poised to revolutionize the pharmaceutical industry by providing innovative communication and marketing strategies. With the assistance of AI tools, pharma marketers can develop personalized sales messages and educational content, improving their engagement with healthcare providers and equipping them to deliver better patient care. ChatGPT’s natural language processing (NLP) technology enables human-like conversations combined with the analysis of vast quantities of data, allowing ph

Pharma 98

Pharma Healthcare Provider Marketing Patients 98

PharmExec

MAY 22, 2023

The market for prescription medicines in the United States was subject to major shifts in use across therapeutic areas in 2022, reflecting changes in patient health needs, the development, and availability of novel medicines, and complex market dynamics.

Prescription 111

Prescription Medicine Patients Marketing 111

Fierce Pharma

MAY 26, 2023

Johnson & Johnson cites rebates and discounts for drug price increases kdunleavy Fri, 05/26/2023 - 07:36

359

359

Nixon Gwilt Law

MAY 26, 2023

As a law firm focused specifically on healthcare innovation, we get really excited about developing areas of the healthcare industry. One area we are particularly excited about? Virtual Reality. Providers are already integrating Virtual Reality ( VR ) into patient care in a variety of ways. For example, using VR to gamify physical therapy exercises for pediatric patients to keep them engaged in their treatment, or to provide targeted exposure therapy in a controlled environment for patients with

Healthcare 119

Healthcare Healthcare Patients Physicians 119

Advertiser: ZoomInfo

Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr

Competition

MedCity News

MAY 25, 2023

It’s clear that services like telehealth and remote patient monitoring have potential to provide value within the healthcare industry, but hospitals and digital health companies need to show payers clearer evidence of the outcomes these care modalities can produce in order to earn reimbursement, panelists argued during MedCity’s INVEST conference.

Patients 116

Patients Healthcare Healthcare 116

Pharmaceutical Technology

MAY 22, 2023

The ongoing patent litigation between CureVac and Pfizer /BioNTech will move to a court in Virginia following a request from Curevac, potentially bringing forward the trial date to sometime in 2024. The Covid-19 pandemic saw a proliferation in novel vaccine technologies being produced rapidly. With the emergence of vaccines came accusations of technology encroachment amongst biotech companies.

Biopharma 116

Biopharma Pharmaceutical Patients Prospecting 116

Clarivate

MAY 22, 2023

From self-driving cars to ChatGPT and Amazon Bedrock, the world is quickly waking up to the enormous potential for artificial intelligence (AI) to change our world. Much discussion has focused on whether this will ultimately be for better or worse; but as with any seismic shift in technology, the answer will depend on how we choose to engage with and deploy the new tools.

Pharma 115

Pharma Healthcare Healthcare Patients 115

MedCity News

MAY 23, 2023

A panel during the MedCity News INVEST conference discussed what digital health technologies need to do to demonstrate return on investment for payers, providers, and other stakeholders.

109

109

Pharmaceutical Technology

MAY 22, 2023

Amid high inflation , the latest banking crisis , and the continued repercussions of Brexit, the talent pool at British universities remains a major draw for British biotech. Now, the country’s possible participation in the EU’s Horizon Europe scheme would serve to boost the industry during a challenging time. Recent negotiations between the UK and the EU have opened the country’s prospects to re-joining the Horizon Europe program, which has been welcomed by biotechs and institutions alike.

Medicine 111

Medicine Prospecting Marketing Government 111

Fierce Pharma

MAY 22, 2023

Pfizer, Moderna among many biopharma giants to post Q1 sales declines, as Novo Nordisk led growth charge kdunleavy Mon, 05/22/2023 - 13:04

Biopharma 281

Biopharma Sales 281

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

European Pharmaceutical Review

MAY 23, 2023

New research by IQVIA and recently published in the 2023 Swiss Biotech Report shows that 20 percent of European biotech companies are now headquartered in Switzerland. Sixty three out of a total of 265 companies settling in Switzerland were biotechs. This makes it the second most important sector after ICT, the research found. 2022 statistics by the Swiss federal government confirm that the trend to base here is continuing.

Pharma 108

Pharma Biopharma Pharmaceutical Medicine 108

MedCity News

MAY 26, 2023

Although there is uncertainty and risk, the implementation of AI with the right compliance framework and infrastructure offers an exciting opportunity to transform healthcare into a new frontier with improved patient outcomes and increased efficiency.

Healthcare 106

Healthcare Healthcare Patients 106

Pharmaceutical Technology

MAY 22, 2023

The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has accepted an investigational new drug application (IND) for SinoMab BioScience’s SM17 to treat asthma. SM17 is a humanised IgG4-k monoclonal antibody that targets IL-17RB to treat asthma, idiopathic pulmonary fibrosis (IPF), atopic dermatitis (AD) and other immunological disorders.

Food and Drug Administration 109

Food and Drug Administration Patients Medical Safety 109

Fierce Pharma

MAY 25, 2023

Johnson & Johnson takes another step in CAR-T race with Bristol Myers in multiple myeloma kdunleavy Thu, 05/25/2023 - 10:52

289

289

Advertiser: ZoomInfo

In times of economic uncertainty, account-based strategies are essential. According to several business analysts and practitioners, ABM is a necessity for creating more predictable revenue. Research shows that nearly three-quarters of marketers (74%) already have the resources needed to build successful ABM programs.

Marketing

PM360

MAY 25, 2023

The world is full of tradeoffs—it’s the way progress is made while proportionately managing risk. When it comes to decentralized clinical trials (DCTs), arguably the most transformative innovation clinical research has seen in decades, the same is true. The new Food and Drug Administration (FDA)’s Decentralized Clinical Trial Draft Guidance issued May 1 st has started to outline guidelines for increased oversight and planning while simultaneously supporting broader DCT adoption.

FDA 104

FDA Food and Drug Administration Medicine Safety 104

MedCity News

MAY 22, 2023

NeuroFlow — a startup that provides behavioral health integration software — struck a new partnership with Atlantic Health System, which will be using the company’s technology across 16 ACO sites. The health system’s goals for the partnership are to expand access to behavioral health professionals, alleviate administrative burden among primary care practices and improve performance in its ACO’s value-based contracts.

106

106

Pharmaceutical Technology

MAY 26, 2023

The US Food and Drug Administration (FDA) has granted priority review for Takeda and HUTCHMED’s new drug application (NDA) for fruquintinib. Fruquintinib is a selective and potent oral VEGFR -1, -2 and -3 receptors inhibitor and is used for the treatment of adults with previously treated metastatic colorectal cancer. Fruquintinib will be the first and only highly selective inhibitor of these receptors approved in the US.

FDA 105

FDA Food and Drug Administration Prescription Patients 105

Fierce Pharma

MAY 22, 2023

Bayer's blockbuster hopeful Nubeqa, AstraZeneca's Forxiga pick up nods from England's NICE zbecker Mon, 05/22/2023 - 10:44

288

288

Advertiser: ZoomInfo

Shifting to an account-based marketing (ABM) strategy can be both exciting and challenging. Well-implemented ABM motions build engagement with high-value accounts and drive impactful campaigns that resonate with your audience. But where do you begin, and how do you progress from crawling to running? Watch now as Demand Gen experts delve into the essentials of each stage of the ABM process.

Marketing

European Pharmaceutical Review

MAY 26, 2023

The UK Chancellor has announced a £650 million life sciences growth package (Life Sci for Growth) to help deliver the Science and Technology framework through reforming regulation, boosting investment and driving up talent and skills. Bringing together 10 different policies, the package includes: A total of £121 million to improve commercial clinical trials to bring new medicines to patients faster Up to £48 million of new money for scientific innovation to prepare for any future health emergenc

Medicine 99

Medicine Pharmaceutical Manufacturing Patients 99

MedCity News

MAY 21, 2023

Krystal Biotech’s Vyjuvek is approved to treat recessive and dominant forms of dystrophic epidermolysis bullosa (DEB), a rare genetic skin disorder. The redosable gene therapy, applied to the skin, delivers a gene that gets cells to produce collagen that DEB patients lack.

FDA 105

FDA Patients Biopharma Pharma 105

Pharmaceutical Technology

MAY 26, 2023

The immuno-oncology market continues to evolve as treatments establish their presence across different types of cancer, having seen approvals in multiple indications in the past decade. While the market was worth over $6 billion in 2012, this has now grown to nearly $48 billion only a decade later, said Avigayil Chalk, PhD, GlobalData’s Senior Oncology and Haematology analyst, at an immuno-oncology webinar held on May 23.

Marketing 105

Marketing Physicians Pharmaceutical Insurance 105

Fierce Pharma

MAY 24, 2023

Biopharma staffers exhausted and susceptible to burnout, report says kdunleavy Wed, 05/24/2023 - 16:52

Biopharma 309

Biopharma 309

Advertiser: ZoomInfo

One of the biggest challenges for any B2B marketer is understanding your prospects’ next move — who is most likely to buy and when. Without these insights, marketing campaigns can feel more like guesswork, with high investment and little return. We’re here to tell you there’s a better way. By tracking buyers’ digital footprints and online activity, such as website visits, product reviews, and spikes in content consumption, you can engage prospects with a message that really resonates.

Marketing

PM360

MAY 25, 2023

Recent research among global pharma professionals revealed that only 4% agree that their digital products regularly succeed and achieve objectives, so what’s going wrong? While businesses are putting time and effort into developing new apps and websites, the impact is often lower than expected. Implementing a design system—an evolving library of reusable visual styles, principles, rules and components—is one way to introduce consistency , improve cadence , and deliver cost efficiencies that can

Pharma 97

Pharma Healthcare Provider Marketing Healthcare 97

MedCity News

MAY 25, 2023

Paxlovid, a Pfizer antiviral awarded FDA emergency authorization in 2021 for treating Covid-19, is now approved for treating adults. Results from a pivotal clinical showed that Paxlovid led to an 86% reduction in Covid-19-related hospitalization or death from any cause compared to a placebo.

FDA 104

FDA Biopharma Pharma 104

Pharmaceutical Technology

MAY 26, 2023

Krystal Biotech has received approval from the US Food and Drug Administration for topical gene therapy VYJUVEK to treat dystrophic epidermolysis bullosa (DEB) in adults and in children aged six months and above. VYJUVEK is designed to address the underlying genetic cause of the disease. An excipient gel applied topically is a key component of the therapy, which is supplied by Krystal’s client, Berkshire Sterile Manufacturing (BSM).

Food and Drug Administration 105

Food and Drug Administration FDA Patients Pharmaceutical 105

Fierce Pharma

MAY 26, 2023

EU regulators recommend yanking authorization for Novartis' sickle cell med Adakveo after phase 3 miss zbecker Fri, 05/26/2023 - 10:48

267

267

Advertiser: ZoomInfo

In this eBook, we’ll run through real-world examples that show how RevOps teams can benefit from modern solutions for the access, management, and activation of their GTM data. Whether you need to improve lead response times, boost adoption of core tools, improve lead qualification, or target and automate your GTM motions, you’ll find examples of how revenue teams are solving some of the toughest problems in modern business.

Leads

PharmaTech

MAY 24, 2023

Process development methods & analytical requirements are integral parts of gene therapy manufacturing. This whitepaper explores the analytical and development approaches needed for success.

Manufacturing 97

Manufacturing 97

MedCity News

MAY 23, 2023

Yaniv Sneor, the co-founder of Mid Atlantic Bio Angels and part of the Ask the Investor sessions at MedCity INVEST this week, explained what his firm looks for in life science startups.

Biopharma 97

Biopharma 97

Pharmaceutical Technology

MAY 25, 2023

Appili Therapeutics has received a US patent for ATI-1501 , a liquid oral reformulation of metronidazole. The patent claims for ATI-1501 were published by the US patent and trademark office under US application no. 18/072,154, filed on 30 November 2022. It covers the composition and preparation methods for ATI-1501 until 2039. Metronidazole is a widely used frontline oral treatment for parasitic and anaerobic bacterial infections.

Food and Drug Administration 105

Food and Drug Administration Prescription Patients Medicine 105

Fierce Pharma

MAY 25, 2023

Apellis scraps pegcetacoplan development in ALS after phase 2 trial flop zbecker Thu, 05/25/2023 - 10:42

300

300

Advertiser: ZoomInfo

Consolidating your tech stack is an effective cost-saving measure that drives GTM efficiency and adds value to your enterprise. With a cohesive, integrated tech stack, your revenue teams can deliver an excellent customer experience that sets you up to win faster than your competitors.